drugset
drugset / Trial / NCT00102310

YM443 in Subjects With Functional Dyspepsia

NCT00102310 ↗

Phase 2 Completed 416 enrolled Astellas Pharma Inc Astellas Pharma US, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.

Timeline

Start
2004-03-10
Primary completion
2006-03-11
Completion
2006-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Acotiamide Small molecule — —

Indications

dyspepsia